Recent Advances in Systemic Chemotherapy for Metastatic Colorectal Cancer

Yuji Miyamoto, Eiji Oki, Hiroshi Saeki, Yoshihiko Maehara, Hideo Baba

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The recent development of chemotherapeutic agents and biomarkers have remarkably improved treatment outcomes of metastatic colorectal cancer (mCRC). However, decision making regarding the choice of therapy for mCRC has been complicated by the availability of many different treatment options. In this review, we will discuss the clinical evidence for current systemic treatment, including the key roles of 3 cytotoxic drugs and oral fluoropyrimidines, the appropriate use of anti-VEGF and anti-EGFR therapy, the significance of RAS mutation status as a predictive marker for anti-EGFR therapy, and new agents for salvage therapy (regorafenib and TAS-102 [TFTD]).

Original languageEnglish
Pages (from-to)15-23
Number of pages9
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume43
Issue number1
Publication statusPublished - Jan 1 2016

Fingerprint

Colorectal Neoplasms
Drug Therapy
Therapeutics
Salvage Therapy
Vascular Endothelial Growth Factor A
Decision Making
Biomarkers
Mutation
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Recent Advances in Systemic Chemotherapy for Metastatic Colorectal Cancer. / Miyamoto, Yuji; Oki, Eiji; Saeki, Hiroshi; Maehara, Yoshihiko; Baba, Hideo.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 43, No. 1, 01.01.2016, p. 15-23.

Research output: Contribution to journalReview article

Miyamoto, Y, Oki, E, Saeki, H, Maehara, Y & Baba, H 2016, 'Recent Advances in Systemic Chemotherapy for Metastatic Colorectal Cancer', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 43, no. 1, pp. 15-23.
Miyamoto, Yuji ; Oki, Eiji ; Saeki, Hiroshi ; Maehara, Yoshihiko ; Baba, Hideo. / Recent Advances in Systemic Chemotherapy for Metastatic Colorectal Cancer. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2016 ; Vol. 43, No. 1. pp. 15-23.
@article{21e3caafa12148db9208ba1acf54e726,
title = "Recent Advances in Systemic Chemotherapy for Metastatic Colorectal Cancer",
abstract = "The recent development of chemotherapeutic agents and biomarkers have remarkably improved treatment outcomes of metastatic colorectal cancer (mCRC). However, decision making regarding the choice of therapy for mCRC has been complicated by the availability of many different treatment options. In this review, we will discuss the clinical evidence for current systemic treatment, including the key roles of 3 cytotoxic drugs and oral fluoropyrimidines, the appropriate use of anti-VEGF and anti-EGFR therapy, the significance of RAS mutation status as a predictive marker for anti-EGFR therapy, and new agents for salvage therapy (regorafenib and TAS-102 [TFTD]).",
author = "Yuji Miyamoto and Eiji Oki and Hiroshi Saeki and Yoshihiko Maehara and Hideo Baba",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "43",
pages = "15--23",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "1",

}

TY - JOUR

T1 - Recent Advances in Systemic Chemotherapy for Metastatic Colorectal Cancer

AU - Miyamoto, Yuji

AU - Oki, Eiji

AU - Saeki, Hiroshi

AU - Maehara, Yoshihiko

AU - Baba, Hideo

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The recent development of chemotherapeutic agents and biomarkers have remarkably improved treatment outcomes of metastatic colorectal cancer (mCRC). However, decision making regarding the choice of therapy for mCRC has been complicated by the availability of many different treatment options. In this review, we will discuss the clinical evidence for current systemic treatment, including the key roles of 3 cytotoxic drugs and oral fluoropyrimidines, the appropriate use of anti-VEGF and anti-EGFR therapy, the significance of RAS mutation status as a predictive marker for anti-EGFR therapy, and new agents for salvage therapy (regorafenib and TAS-102 [TFTD]).

AB - The recent development of chemotherapeutic agents and biomarkers have remarkably improved treatment outcomes of metastatic colorectal cancer (mCRC). However, decision making regarding the choice of therapy for mCRC has been complicated by the availability of many different treatment options. In this review, we will discuss the clinical evidence for current systemic treatment, including the key roles of 3 cytotoxic drugs and oral fluoropyrimidines, the appropriate use of anti-VEGF and anti-EGFR therapy, the significance of RAS mutation status as a predictive marker for anti-EGFR therapy, and new agents for salvage therapy (regorafenib and TAS-102 [TFTD]).

UR - http://www.scopus.com/inward/record.url?scp=84965094572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965094572&partnerID=8YFLogxK

M3 - Review article

C2 - 26809522

AN - SCOPUS:84965094572

VL - 43

SP - 15

EP - 23

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 1

ER -